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Optimization of liposomal encapsulation for ceftazidime 
for developing a potential eye drop formulation
Abstract
Ceftazidime is a broad spectrum third generation cephalosporin antibiotic which is effective mainly against 
Gram-negative bacteria such as Pseudomonas aeruginosa, Acinetobacter and Enterobacteriaceae, the pathogens 
which most often cause ophthalmological infections. Unlike other commonly used beta lactam antibiotics, 
ceftazidime is resistant to several types of beta lactamases (e.g., TEM, SHV and PSE-1). Because of these advantages, 
ceftazidime is used in the treatment of eye infections. However, ceftazidime undergoes rapid degradation in aqueous 
solutions therefore eye drops containing ceftazidime in aqueous solutions are not commercially manufactured. In 
the present study, liposomal encapsulations of ceftazidime with various lipid compositions, hydrating solutions 
and pH-values have been studied in order to optimize liposomal composition for a potential eye drop formulation.
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Introduction
Ceftazidime is a third generation semisynthetic, broad-
spectrum cephalosporin antibiotic for parenteral 
administration. Like other third generation cephalosporins, 
it has a broad spectrum activity against Gram-positive 
and Gram-negative (e.g., Neisseria gonorrhoeae, 
Enterobacteriaceae, Acinetobacter) bacteria [Figure 1]. 
However, unlike most third-generation agents, it is active 
against Pseudomonas aeruginosa. Furthermore, ceftazidime 
is resistant to several types of beta lactamases (e.g., TEM, 
SHV and PSE-1). Thus, ceftazidime is usually reserved for the 
treatment of serious lower airway’s infections, septicemia and 
cerebrospinal meningitis. Ceftazidine is the first line treatment 
for the rare tropical infection, melioidosis.[1-3] Ceftazidime 
is usually given intravenous or intramuscular. Every 
8-12 h (2-3 times a day), with daily dosages of 500-6,000 mg, 
determined by the indication, infection severity and/or renal 
function of the patient. Ceftazidime pentahydrate containing 
products are marketed under various trade names such 
as Cefzim® (Pharco B International), Fortum® (GSK) and 
Fortaz® (GSK).
Ceftazidime is also used for the treatment of ophthalmological 
infections caused in particular by P. aeruginosa. Pseudomonas 
is among the principal pathogens associated with corneal ulcers 
and ceftazidime is the only third generation cephalosporin 
with good coverage against it.[2] However, ceftazidime 
undergoes rapid degradation in aqueous solutions, resulting 
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Figure 1: Chemical structure of ceftazidime
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in the opening of the beta-lactam ring. The rate of degradation 
depends – among others - on temperature, light, composition 
of the solvent, pH and ceftazidime concentration.[1,4] Therefore, 
eye drops containing ceftazidime in aqueous solutions are not 
commercially manufactured.
In the present study, liposomal encapsulations of ceftazidime 
with various lipid compositions and hydrating solutions have 
been studied in order to develop novel eye drop formulations 
to treat ophthalmological infections.
Materials and Methods
The lipids used in these experiments were 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 
1,2-dipalmitoyl-sn-glycero-3-phospho-(1’-rac-glycerol) 
(sodium salt) (DPPG) and 1,2-di-O-octadecenyl-3-
trimethylammonium propane (chloride salt) (DOTMA) from 
Avanti Polar Lipids Inc. (Alabaster, AL, USA). Ceftazidime 
and cholesterol were purchased from Sigma Aldrich 
(St. Louis, MO, USA). Absolute ethanol (Sigma Aldrich, 
St. Louis, MO, USA) was used as the solvent to dissolve 
the lipids. Sodium phosphate, monobasic and dibasic 
(J T Baker, Phillipsburg, NJ, USA) were used to prepare the 
buffer solutions.
Preparation of liposomes
Lipid mixtures were prepared by combining the appropriate 
lipids in 9:1 molar ratio (DPPC + DPPG, DPPC + DOTMA, 
DPPC + cholesterol).
Multilamellar vesicles were prepared using the dehydration/
rehydration method. The mixture of chloroform and 
ethanol (2:1 v/v) was used to dissolve the lipid mixtures. A thin 
lipid film was formed in a round bottom flask by evaporating 
the solvent from the lipid solution in a rotary evaporatior at 
water bath temperature of 45°C for 30 min and at the room 
temperature (25°C) for 20 min under constant flow of argon 
gas. The dry lipid films were stored in a desiccator at the room 
temperature.
For ceftazidime encapsulation, the antibiotic containing 
hydrating solution (30 mg/mL) was added at room 
temperature to the liposome tube in five equal aliquots to 
reach the final volume (1 mL). 0.1 M phosphate buffer, 0.9% 
saline, 5% dextrose and 10% sucrose at pH 7.4 – containing 
ceftazidime – were used as hydrating solutions. After the 
addition of hydrating solution, the round bottom flask was 
vortexed to ensure the homogeneity of the mixture. The final 
lipid concentration was 30 mg/mL in each case, resulting in 
about a 1.33-1 ceftazidime to lipid ratio.
Measurement of encapsulation effi ciency
Freshly prepared ceftazidime-liposomes (1 mL) were 
centrifuged with the Galaxy 16DH eppendrof centrifuge 
(2 × 10 min, 13,000g) through Nanosep 10K Omega 
Centrifugal Filter Devices (PALL Life Science Inc.) with a cut-off 
value of 10 kDa to separate the liposomes from the solution.
The encapsulation efficiencies for ceftazidime were 
determined by spectrophotometry (Shimadzu ultraviolet-
visible spectrophotometer, 2101-PC) at a wavelength of 
296 nm. The absorbance values of the ceftazidime containing 
hydrating solutions (Absi) and the absorbance of the filtered 
outer phase of liposomal samples (Absf) were determined.
The encapsulation efficiency was determined using the 
following equation:
EE = (Absi − Absf)/Absi × 100.
Results
Throughout our experiments for liposomal encapsulation, 
3% ceftazidime concentrations were used. According to the 
literature data, 1% ceftazidime eye drops are applied in the 
treatment of infections of the external eye structures while 5% 
formulations are used in case of severe infections of front or 
internal eye structures.[1]
The composition of the liposome affects the amounts 
of ceftazidime encapsulated. Among the compositions 
tested throughout our study, the highest ceftazidime 
encapsulation − 17.72 ± 0.92% – was achieved using DPPC: 
DPPG combination in 9:1 molar ratio [Table 1]. The presence 
of the cationic lipid DOTMA decreased the ceftazidime 
encapsulation value (13.03 ± 2.63%). This observation 
can be explained with electrostatic interactions between 
the lipid bilayer and drug negatively influencing the rate of 
encapsulation. The positively charged quaternary ammonium 
of ceftazidime may play a significant role in the above 
mentioned fact.
As ceftazidime has a polar character (log P = −1.6), deep 
immersion of ceftazidime molecules into the apolar bilayer is 
not suspected. Instead of this kind of interaction molecular 
forces between the lipid head groups and drug, e.g., through 
hydrogen bonds can be responsible for the encapsulation 
of ceftazidime. This presumption can be strengthened with 
the encapsulation efficiency data [Table 1]. For liposomes 
comprised of DPPC and DPPG, where the phospholipid 
bilayer is relatively rigid due to the completely saturated 
fatty acid, palmitic acid, the encapsulation efficiency 
was found to be the highest. The presence of cholesterol, 
acting as a fluidity increasing agent, did not lead to higher 
encapsulation of ceftazidime. It allows to suspect that 
membrane fluidity may not be the main factor influencing 
ceftazidime encapsulation.
While considering the hydrating solution, all the tested 
solutions resulted in almost similar encapsulation 
efficiencies [Table 2], with the highest mean value for 
ceftazidime liposomes prepared with phosphate buffer. 
However, the use of dextrose and sucrose for hydration may 
increase the possibility of microbial contamination of the 
liposomal preparations during storage.
Taking into consideration one of the major needs of 
ophthalmic products – the formulation should possess 
physiologic pH value. The physiological tear pH range is 
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6.5-7.6; the mean value was 7.0.[5] Regarding the pH, the 
maximal ceftazidime stability in aqueous solutions occurs 
at pH 4.5-6.5.[4] On this basis the optimal pH for ceftazidime 
eye drops is about pH 6.5. Using osmotic phosphate buffers 
for hydration with pH 6.4; 7.4 and 8.4, significant difference 
cannot be observed between the ceftazidime encapsulation 
efficiency values (P > 0.05) [Table 3]. Thus, the criterion of 
optimal pH-value, being necessary for the formulation of 
ophthalmic preparations, can be fulfilled.
Comparing our ceftazidime encapsulation results with the 
literature data it is important to note, that ceftazidime and 
cefepime co-encapsulation into unilamellar vesicles was 
Table 1: Determination of encapsulation efficiency (%) 
for ceftazidime (3 mg/mL) in liposomes with various 
compositions; as hydrating solution phosphate 
buffer (pH 7.4) was used (n=3)
Lipid mixture used to prepare 
liposomes (9:1 molar ratio)
Encapsulation efficiency 




SD: Standard deviation, DPPC: 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine, DPPG: 1,2-dipalmitoyl-sn-glycero-3-phospho-
(1’-rac-glycerol) (sodium salt), DOTMA: 1,2-di-O-octadecenyl-3-
trimethylammonium propane (chloride salt)
Table 2: Determination of encapsulation efficiency (%) 
for ceftazidime in DPPC:DPPG (9:1 molar ratio) liposomes 









SD: Standard deviation, DPPC: 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine, DPPG: 1,2-dipalmitoyl-sn-glycero-3-phospho-
(1’-rac-glycerol) (sodium salt)
Table 3: Determination of encapsulation efficiency (%) 
for ceftazidime in DPPC:DPPG (9:1 molar ratio) 
liposomes while varying the pH of hydrating 
phosphate buffer (n=3)
pH of the buffer 
solution
Encapsulation efficiency 




SD: Standard deviation, DPPC: 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine, DPPG: 1,2-dipalmitoyl-sn-glycero-3-phospho-
(1’-rac-glycerol) (sodium salt)
examined by Torres et al.[6] In their case, the average diameter 
of liposomes was 131.88 nm and encapsulation efficiency 
for cefepime and ceftazidime were 2.29% and 5.77%, 
respectively.[6] Our ceftazidime multilamellar vesicles (MLVs) 
with an average diameter of 2 μm prepared from DPPC 
show higher entrapment efficiency, 17.72 ± 0.92%, than 
small unilamellare vesicle (SUV) samples of Torres et al. 
This observation – beyond the question of co-encapsulation 
versus simple encapsulation – may be the consequence of the 
multilamellar structure applied in our present study. In our 
earlier experiments, the electron paramagnetic resonance 
signals out of the liposomes were quenched by paramagnetic 
relaxation and we observed for the incorporated aqueous 
volumes about 7% and 2% in case of MLVs and SUVs, 
respectively.[7-10] Ceftazidime encapsulation efficiency values 
in each case are higher than the ratio of the encapsulated 
aqueous volume highlighting the role of potential molecular 
interactions between carrier system and encapsulated 
drug and underlining the importance of further liposomal 
encapsulation studies.
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